The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry.
It was found by DNA flow cytometry that AT-125 preferentially inhibited the cell cycle progression in G1-phase of BT-20 more so than MCF-7 breast carcinoma cells in vitro and that cells washed free of the drug now possessed S-phase DNA content. It was also found that gamma-glutamyl transpeptidase levels were more than 2 times higher in BT-20 than in MCF-7 cells.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D003584:Cytological Techniques; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007555:Isoxazoles; D010080:Oxazoles; D005723:gamma-Glutamyltransferase; C006303:acivicin; D005998:Glycine